{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:22:32Z","timestamp":1785558152517,"version":"3.56.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bneo.2024.100010","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T16:13:51Z","timestamp":1712938431000},"page":"100010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A novel application of XPO1 inhibition for the treatment of myelofibrosis"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6718-2974","authenticated-orcid":false,"given":"Megan","family":"Metzger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1208-9260","authenticated-orcid":false,"given":"Zachary M.","family":"Avigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6217","authenticated-orcid":false,"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6167-4322","authenticated-orcid":false,"given":"Julian","family":"Waksal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bneo.2024.100010_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100010_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2024.100010_bib3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ajh.26821","article-title":"The International Consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms","volume":"98","author":"Thiele","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100010_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2007.1.346","article-title":"Biology and treatment of primary myelofibrosis","volume":"2007","author":"Hoffman","year":"2007","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.bneo.2024.100010_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clml.2020.01.008","article-title":"The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication","volume":"20","author":"Marcellino","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"17","key":"10.1016\/j.bneo.2024.100010_bib7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.bneo.2024.100010_bib8","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2005-10-4169","article-title":"Role of transforming growth factor-\u03b2 in hematologic malignancies","volume":"107","author":"Dong","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100010_bib9","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1182\/blood-2002-02-0485","article-title":"Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors","volume":"100","author":"Giraudier","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2024.100010_bib10","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100010_bib11","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2002-09-2839","article-title":"Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO","volume":"101","author":"Chagraoui","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100010_bib12","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1158\/0008-5472.CAN-04-2339","article-title":"Role for the nuclear factor \u03baB pathway in transforming growth factor-\u03b21 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression","volume":"65","author":"Komura","year":"2005","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.bneo.2024.100010_bib13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.bneo.2024.100010_bib14","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100010_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","article-title":"Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval","volume":"101","author":"Verstovsek","year":"2022","journal-title":"Ann Hematol"},{"issue":"21","key":"10.1016\/j.bneo.2024.100010_bib18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V122.21.393.393","article-title":"Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF)","volume":"122","author":"Pardanani","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2024.100010_bib19","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.bneo.2024.100010_bib20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"key":"10.1016\/j.bneo.2024.100010_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106338","article-title":"Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported","volume":"91","author":"Masarova","year":"2020","journal-title":"Leuk Res"},{"issue":"13","key":"10.1016\/j.bneo.2024.100010_bib23","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"10373","key":"10.1016\/j.bneo.2024.100010_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.bneo.2024.100010_bib25","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","volume":"10","author":"Gerds","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib26","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2018-99-115407","article-title":"Janus kinase (Jak) 1 inhibition affects both megakaryopoiesis and thrombopoiesis","volume":"132","author":"Jarocha","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100010_bib27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.bneo.2024.100010_bib28","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bneo.2024.100010_bib29","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/cells10051034","article-title":"Next generation therapeutics for the treatment of myelofibrosis","volume":"10","author":"Tremblay","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.bneo.2024.100010_bib30","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.bneo.2024.100010_bib31","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood-2023-173509","article-title":"Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis","volume":"142","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100010_bib33","doi-asserted-by":"crossref","DOI":"10.4155\/fsoa-2018-0115","article-title":"Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy","volume":"5","author":"Alqahtani","year":"2019","journal-title":"Future Sci OA"},{"key":"10.1016\/j.bneo.2024.100010_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a driver of clonal evolution in myeloproliferative neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"issue":"32","key":"10.1016\/j.bneo.2024.100010_bib36","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"10.1016\/j.bneo.2024.100010_bib37","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase III MANIFEST-2: pelabresib\u00a0+ ruxolitinib vs placebo\u00a0+ ruxolitinib in JAK inhibitor treatment-naive myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib38","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2023-179141","article-title":"Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study","volume":"142","author":"Rampal","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2024.100010_bib39","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/ajh.26349","article-title":"2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management","volume":"96","author":"Ali","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100010_bib40","first-page":"721","article-title":"Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis","volume":"23","author":"Mascarenhas","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"3","key":"10.1016\/j.bneo.2024.100010_bib41","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41375-021-01483-z","article-title":"Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms","volume":"36","author":"Balasubramanian","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2024.100010_bib42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.bneo.2024.100010_bib43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"Turner","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib44","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1182\/blood-2023-188432","article-title":"XPO1 inhibitor triggers autophagy of TP53-mutated Burkitt's lymphoma cells","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100010_bib45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11523-020-00758-2","article-title":"Targeting nuclear export proteins in multiple myeloma therapy","volume":"15","author":"Theodoropoulos","year":"2020","journal-title":"Target Oncol"},{"issue":"34","key":"10.1016\/j.bneo.2024.100010_bib46","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1200\/JCO.2016.67.5637","article-title":"Targeting cancer at the nuclear pore","volume":"34","author":"Azmi","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100010_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tcb.2007.02.003","article-title":"CRM1-mediated nuclear export: to the pore and beyond","volume":"17","author":"Hutten","year":"2007","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.bneo.2024.100010_bib48","first-page":"82","article-title":"The RanGTP pathway: from nucleo-cytoplasmic transport to spindle assembly and beyond","volume":"3","author":"Cavazza","year":"2015","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100010_bib49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein XPO1 \u2014 from biology to targeted therapy","volume":"18","author":"Azmi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bneo.2024.100010_bib50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"issue":"20","key":"10.1016\/j.bneo.2024.100010_bib51","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","article-title":"Prognostic impact and targeting of CRM1 in acute myeloid leukemia","volume":"121","author":"Kojima","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2024.100010_bib52","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.bneo.2024.100010_bib53","doi-asserted-by":"crossref","DOI":"10.25011\/cim.v32i6.10668","article-title":"Prognostic value of CRM1 in pancreas cancer","volume":"32","author":"Huang","year":"2009","journal-title":"Clin Invest Med"},{"issue":"D1","key":"10.1016\/j.bneo.2024.100010_bib54","doi-asserted-by":"crossref","first-page":"D338","DOI":"10.1093\/nar\/gks936","article-title":"ValidNESs: a database of validated leucine-rich nuclear export signals","volume":"41","author":"Fu","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bneo.2024.100010_bib55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2016.03.020","article-title":"Importins and exportins as therapeutic targets in cancer","volume":"164","author":"Mahipal","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bneo.2024.100010_bib56","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.bneo.2024.100010_bib57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2014.04.005","article-title":"Clinical translation of nuclear export inhibitors in cancer","volume":"27","author":"Senapedis","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.bneo.2024.100010_bib58","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ceb.2015.04.012","article-title":"Nuclear transport factors: global regulation of mitosis","volume":"35","author":"Forbes","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.bneo.2024.100010_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","article-title":"Selective inhibitors of nuclear export (SINE) in hematological malignancies","volume":"4","author":"Das","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib60","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2024.100010_bib61","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1186\/s12885-015-1936-z","article-title":"KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models","volume":"15","author":"Gravina","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bneo.2024.100010_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/srep14391","article-title":"Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor","volume":"5","author":"Marcus","year":"2015","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.bneo.2024.100010_bib63","doi-asserted-by":"crossref","first-page":"F1179","DOI":"10.1152\/ajprenal.00406.2014","article-title":"Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels","volume":"307","author":"Tan","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"48","key":"10.1016\/j.bneo.2024.100010_bib64","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bneo.2024.100010_bib65","first-page":"1","article-title":"The selective inhibitor of nuclear export compound, selinexor, inhibits NF-\u03baB and induces anti-non-small cell lung cancer activity regardless of p53 status","volume":"2","author":"Crochiere","year":"2016","journal-title":"Int J Cancer Res Mol Mech"},{"issue":"48","key":"10.1016\/j.bneo.2024.100010_bib66","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","article-title":"XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma","volume":"7","author":"Turner","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.bneo.2024.100010_bib67","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-16-2632","article-title":"Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of I\u03baB and downregulation of survivin","volume":"23","author":"Nair","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bneo.2024.100010_bib68","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1535-7163.MCT-18-1319","article-title":"Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-\u03baB pathway in preclinical models of pediatric high-grade glioma","volume":"19","author":"DeSisto","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.bneo.2024.100010_bib69","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2014-08-588855","article-title":"shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance","volume":"125","author":"Khorashad","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bneo.2024.100010_bib70","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","article-title":"Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias","volume":"122","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100010_bib71","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.18632\/oncotarget.13485","article-title":"Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma","volume":"8","author":"Garg","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bneo.2024.100010_bib72","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/1535-7163.MCT-13-0416","article-title":"XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer","volume":"13","author":"Cheng","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.bneo.2024.100010_bib73","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/leu.2014.9","article-title":"Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells","volume":"28","author":"Zhong","year":"2014","journal-title":"Leukemia"},{"issue":"39","key":"10.1016\/j.bneo.2024.100010_bib74","doi-asserted-by":"crossref","first-page":"25529","DOI":"10.18632\/oncotarget.25368","article-title":"Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death","volume":"9","author":"Argueta","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bneo.2024.100010_bib75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.canlet.2016.09.016","article-title":"Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone","volume":"383","author":"Muqbil","year":"2016","journal-title":"Cancer Lett"},{"issue":"3","key":"10.1016\/j.bneo.2024.100010_bib76","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/bloodadvances.2019000359","article-title":"Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies","volume":"4","author":"Fischer","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.bneo.2024.100010_bib77","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10262","key":"10.1016\/j.bneo.2024.100010_bib78","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40259-021-00514-6","article-title":"Targeting nuclear export proteins in multiple myeloma therapy","volume":"36","author":"Richard","year":"2022","journal-title":"BioDrugs"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib80","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1182\/blood-2023-190413","article-title":"Sequential administration of selinexor and CAR-T therapy in relapsed\/ refractory multiple myeloma","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2024.100010_bib81","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100010_bib82","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-20-4929","article-title":"Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: results of a phase I study","volume":"27","author":"Seymour","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2023-184581","article-title":"Selinexor in combination with venetoclax and azacitidine for newly diagnosed (ND) unfit acute myeloid leukemia (AML): a multicenter, open-label prospective study","volume":"142","author":"Yang","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib84","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1182\/blood-2023-183101","article-title":"Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2: a single-center, single-arm, phase Ib\/II trial","volume":"142","author":"Ma","year":"2023","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bneo.2024.100010_bib85","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-21-3867","article-title":"Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced b-cell malignancies: a phase I study","volume":"28","author":"Stephens","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2024.100010_bib86","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1078-0432.CCR-21-2225","article-title":"A\u00a0phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.bneo.2024.100010_bib87","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1200\/JCO.21.01829","article-title":"Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial","volume":"40","author":"Gounder","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100010_bib88","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-19-1728","article-title":"Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma","volume":"26","author":"Azmi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bneo.2024.100010_bib89","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1634\/theoncologist.2019-0231","article-title":"A\u00a0phase II trial of selinexor (KPT-330) for metastatic triple-negative breast cancer","volume":"24","author":"Shafique","year":"2019","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bneo.2024.100010_bib90","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1634\/theoncologist.2017-0624","article-title":"A\u00a0phase II trial of selinexor, an oral selective inhibitor of nuclear export compound, in abiraterone- and\/or enzalutamide-refractory metastatic castration-resistant prostate cancer","volume":"23","author":"Wei","year":"2018","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.bneo.2024.100010_bib91","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2174\/1568009620666200628105727","article-title":"Selinexor (KPT-330), an oral selective inhibitor of nuclear export (SINE) compound, in combination with FOLFOX in patients with metastatic colorectal cancer (mCRC) - final results of the phase I trial SENTINEL","volume":"20","author":"Nilsson","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"issue":"36 suppl","key":"10.1016\/j.bneo.2024.100010_bib92","doi-asserted-by":"crossref","first-page":"427956","DOI":"10.1200\/JCO.2023.41.36_suppl.427956","article-title":"Long-term follow up of selinexor maintenance in patients with TP53wt advanced or recurrent endometrial cancer: a pre-specified subgroup analysis from the phase 3 ENGOT-EN5\/GOG-3055\/SIENDO study","volume":"41","author":"Slomovitz","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2024.100010_bib93","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428194.2020.1775210","article-title":"Selinexor for advanced hematologic malignancies","volume":"61","author":"Walker","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"15 suppl","key":"10.1016\/j.bneo.2024.100010_bib94","article-title":"SIENDO\/ENGOT-EN5\/GOG-3055: a randomized phase 3 trial of maintenance elinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer","volume":"39","author":"Vergote","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4 suppl","key":"10.1016\/j.bneo.2024.100010_bib95","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2022.40.4_suppl.110","article-title":"Open-label phase 1\/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer","volume":"40","author":"Golan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bneo.2024.100010_bib96","doi-asserted-by":"crossref","first-page":"S756","DOI":"10.1016\/j.annonc.2020.08.1247","article-title":"1124P phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: the melanoma experience","volume":"31(4 suppl)","author":"Glitza","year":"2020","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.bneo.2024.100010_bib97","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.bneo.2024.100010_bib98","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.bneo.2024.100010_bib99","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.bneo.2024.100010_bib100","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","article-title":"Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis","volume":"130","author":"Machlus","year":"2017","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.bneo.2024.100010_bib101","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib102","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","article-title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","volume":"31","author":"Etchin","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2024.100010_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100789","article-title":"The \u2018comeback\u2019 of selinexor: from toxic to tolerable","volume":"46","author":"Hashmi","year":"2022","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2024.100010_bib104","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-18-0959","article-title":"Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis","volume":"25","author":"Yan","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib105","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/blood-2023-180134","article-title":"Activity of selinexor as a single agent and synergistic activity with approved\/investigational myelofibrosis therapies in\u00a0vitro","volume":"142","author":"Maloof","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib106","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2023-186674","article-title":"Use of combination therapies including the XPO1 inhibitor selinexor in is a potential effective therapeutic strategy to treat myelofibrosis patients","volume":"142","author":"Lu","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib107","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2021-153940","article-title":"A\u00a0phase 2 study to evaluate the efficacy and safety of selinexor in patients with myelofibrosis refractory or intolerant to JAK inhibitors","volume":"138","author":"Tantravahi","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib108","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2023-181720","article-title":"A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Na\u00efve Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)","volume":"142","author":"Scandura","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib109","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1182\/blood-2023-180844","article-title":"Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-na\u00efve patients with myelofibrosis: long term follow up from XPORT-MF-034 suggestive of disease modification","volume":"142","author":"Tantravahi","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100010_bib110","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1182\/blood-2023-180695","article-title":"A\u00a0global, phase 3, randomized, double-blind study to evaluate safety and efficacy of selinexor, an XPO-1 inhibitor, in combination with ruxolitinib in JAK inhibitor-na\u00efve myelofibrosis (XPORT-MF-034)","volume":"142","author":"Maher","year":"2023","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T23:48:25Z","timestamp":1719359305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2950328024000104"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100010","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel application of XPO1 inhibition for the treatment of myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100010"}}